AEON Biopharma (AEON)
XASE:AEON
Want to see AEON full AI Analyst Report?
AEON Stock Chart & Stats
$1.10
-$0.02(-9.37%)
At close: 4:00 PM EST
$1.10
-$0.02(-9.37%)
Day’s Range― - ―
52-Week Range$0.39 - $1.45
Previous CloseN/A
Volume17.80M
Average Volume (3M)273.24K
Market Cap
$26.57M
Enterprise Value$45.04M
Total Cash (Recent Filing)$3.01M
Total Debt (Recent Filing)$35.74M
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.24
Shares Outstanding25,303,059
10 Day Avg. Volume605,674
30 Day Avg. Volume273,237
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.63
Enterprise Value/Market Cap1.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.25K
Enterprise Value/Ebitda-2.68
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-50.4
Revenue Forecast (FY)$16.30M
Bulls Say, Bears Say
Bulls Say
Cost ManagementR&D expenses declined 50.8% YoY to $4.4M, which were below the estimate, indicating effective cost management.
Regulatory ApprovalAeon finds alignment with the FDA on key biosimilar pathway requirements, boosting confidence in potential regulatory approval.
Bears Say
Funding UncertaintyGiven the uncertainty in funding, the price target is adjusted to $5 from $6, reflecting potential financial challenges.
Production DependencyAeon relies on Daewoong to manufacture ABP-450, and any production issues with Daewoong could adversely impact Aeon.
AEON Biopharma News
AEON FAQ
What was AEON Biopharma’s price range in the past 12 months?
AEON Biopharma lowest stock price was $0.39 and its highest was $1.45 in the past 12 months.
What is AEON Biopharma’s market cap?
AEON Biopharma’s market cap is $26.57M.
When is AEON Biopharma’s upcoming earnings report date?
AEON Biopharma’s upcoming earnings report date is May 20, 2026 which is in 22 days.
How were AEON Biopharma’s earnings last quarter?
AEON Biopharma released its earnings results on Mar 30, 2026. The company reported -$5.24 earnings per share for the quarter, missing the consensus estimate of -$0.205 by -$5.035.
Is AEON Biopharma overvalued?
According to Wall Street analysts AEON Biopharma’s price is currently Overvalued.
Does AEON Biopharma pay dividends?
AEON Biopharma does not currently pay dividends.
What is AEON Biopharma’s EPS estimate?
AEON Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AEON Biopharma have?
AEON Biopharma has 25,303,059 shares outstanding.
What happened to AEON Biopharma’s price movement after its last earnings report?
AEON Biopharma reported an EPS of -$5.24 in its last earnings report, missing expectations of -$0.205. Following the earnings report the stock price went down -0.404%.
Which hedge fund is a major shareholder of AEON Biopharma?
Currently, no hedge funds are holding shares in AEON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AEON Biopharma
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
Technical Analysis
Imunon
―
XTL Biopharmaceuticals Sponsored ADR
―
Aptorum Group
―
―
TransCode Therapeutics
―
Ownership Overview
42.94% Insiders
0.58% Mutual Funds
0.08% Other Institutional Investors
56.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---